{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:14:10Z","timestamp":1791386050445,"version":"4.3.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["7184211"],"award-info":[{"award-number":["7184211"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81801402"],"award-info":[{"award-number":["81801402"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Natural Science Foundation Program and Scientific Research Key Program of Beijing Municipal Commission of Education","award":["KM201610025023"],"award-info":[{"award-number":["KM201610025023"]}]},{"name":"Beijing key clinical specialty project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod. Sci."],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s43032-020-00202-w","type":"journal-article","created":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T15:10:42Z","timestamp":1596467442000},"page":"1848-1856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Inhibition of Lnc-OC1 Induced Cell Apoptosis and Decreased Cell Viability by Releasing miR-34a and Inhibiting PD-L1 in Endometrial Carcinoma"],"prefix":"10.1007","volume":"27","author":[{"given":"Yun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-xuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"issue":"5","key":"202_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359\u201386. https:\/\/doi.org\/10.1002\/ijc.29210.","journal-title":"Int J Cancer"},{"issue":"1","key":"202_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/107327480901600102","volume":"16","author":"N Bansal","year":"2009","unstructured":"Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009;16(1):8\u201313. https:\/\/doi.org\/10.1177\/107327480901600102.","journal-title":"Cancer Control"},{"issue":"1","key":"202_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","volume":"15","author":"JV Bokhman","year":"1983","unstructured":"Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10\u20137. https:\/\/doi.org\/10.1016\/0090-8258(83)90111-7.","journal-title":"Gynecol Oncol"},{"key":"202_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.gynor.2013.02.007","volume":"5","author":"ES Wu","year":"2013","unstructured":"Wu ES, Shih Ie M, Diaz-Montes TP. Dedifferentiated endometrioid adenocarcinoma: an under-recognized but aggressive tumor? Gynecol Oncol Case Rep. 2013;5:25\u20137. https:\/\/doi.org\/10.1016\/j.gynor.2013.02.007.","journal-title":"Gynecol Oncol Case Rep"},{"issue":"10","key":"202_CR5","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1097\/01.pas.0000171003.72352.9a","volume":"29","author":"B Altrabulsi","year":"2005","unstructured":"Altrabulsi B, Malpica A, Deavers MT, Bodurka DC, Broaddus R, Silva EG. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol. 2005;29(10):1316\u201321. https:\/\/doi.org\/10.1097\/01.pas.0000171003.72352.9a.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"202_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/01.pgp.0000183048.22588.18","volume":"25","author":"EG Silva","year":"2006","unstructured":"Silva EG, Deavers MT, Bodurka DC, Malpica A. Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol. 2006;25(1):52\u20138. https:\/\/doi.org\/10.1097\/01.pgp.0000183048.22588.18.","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"202_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1080\/00313020601159494","volume":"39","author":"EG Silva","year":"2007","unstructured":"Silva EG, Deavers MT, Malpica A. Undifferentiated carcinoma of the endometrium: a review. Pathology. 2007;39(1):134\u20138. https:\/\/doi.org\/10.1080\/00313020601159494.","journal-title":"Pathology."},{"issue":"6","key":"202_CR8","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/modpathol.2010.41","volume":"23","author":"LJ Tafe","year":"2010","unstructured":"Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol. 2010;23(6):781\u20139. https:\/\/doi.org\/10.1038\/modpathol.2010.41.","journal-title":"Mod Pathol"},{"issue":"3","key":"202_CR9","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.ygyno.2016.09.021","volume":"143","author":"Y Fu","year":"2016","unstructured":"Fu Y, Biglia N, Wang Z, Shen Y, Risch HA, Lu L, et al. Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer. Gynecol Oncol. 2016;143(3):642\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2016.09.021.","journal-title":"Gynecol Oncol"},{"key":"202_CR10","doi-asserted-by":"publisher","first-page":"175883591987464","DOI":"10.1177\/1758835919874649","volume":"11","author":"H Jiang","year":"2019","unstructured":"Jiang H, Li Y, Li J, Zhang X, Niu G, Chen S, et al. Long noncoding RNA LSINCT5 promotes endometrial carcinoma cell proliferation, cycle, and invasion by promoting the Wnt\/beta-catenin signaling pathway via HMGA2. Ther Adv Med Oncol. 2019;11:1758835919874649. https:\/\/doi.org\/10.1177\/1758835919874649.","journal-title":"Ther Adv Med Oncol"},{"key":"202_CR11","doi-asserted-by":"publisher","unstructured":"Ferlita A, Battaglia R, Andronico F, Caruso S, Cianci A, Purrello M et al. Non-coding RNAs in endometrial physiopathology. Int J Mol Sci. 2018;19(7). doi:https:\/\/doi.org\/10.3390\/ijms19072120.","DOI":"10.3390\/ijms19072120"},{"key":"202_CR12","doi-asserted-by":"publisher","unstructured":"Zhang XH, Hu P, Xie YQ, Kang YJ, Li M. Long noncoding RNA HOTAIR promotes endometrial carcinoma cell proliferation by binding to PTEN via the activating phosphatidylinositol 3-kinase\/Akt signaling pathway. Mol Cell Biol. 2019;39(23). doi:https:\/\/doi.org\/10.1128\/MCB.00251-19.","DOI":"10.1128\/MCB.00251-19"},{"issue":"15","key":"202_CR13","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.26355\/eurrev_201808_15617","volume":"22","author":"L Zhang","year":"2018","unstructured":"Zhang L, Wang DL, Yu P. LncRNA H19 regulates the expression of its target gene HOXA10 in endometrial carcinoma through competing with miR-612. Eur Rev Med Pharmacol Sci. 2018;22(15):4820\u20137. https:\/\/doi.org\/10.26355\/eurrev_201808_15617.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3\u20134","key":"202_CR14","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1159\/000452577","volume":"40","author":"D Wang","year":"2016","unstructured":"Wang D, Wang N, Long Z, Ren X. Long non-coding RNA BANCR promotes endometrial cancer cell proliferation and invasion by regulating MMP2 and MMP1 via ERK\/MAPK signaling pathway. Cell Physiol Biochem. 2016;40(3\u20134):644\u201356. https:\/\/doi.org\/10.1159\/000452577.","journal-title":"Cell Physiol Biochem"},{"issue":"3","key":"202_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jgg.2018.03.001","volume":"45","author":"F Tao","year":"2018","unstructured":"Tao F, Tian X, Lu M, Zhang Z. A novel lncRNA, Lnc-OC1, promotes ovarian cancer cell proliferation and migration by sponging miR-34a and miR-34c. J Genet Genomics. 2018;45(3):137\u201345. https:\/\/doi.org\/10.1016\/j.jgg.2018.03.001.","journal-title":"J Genet Genomics"},{"issue":"34","key":"202_CR16","doi-asserted-by":"publisher","first-page":"14240","DOI":"10.1073\/pnas.1017536108","volume":"108","author":"CI Hwang","year":"2011","unstructured":"Hwang CI, Matoso A, Corney DC, Flesken-Nikitin A, Korner S, Wang W, et al. Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci U S A. 2011;108(34):14240\u20135. https:\/\/doi.org\/10.1073\/pnas.1017536108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"202_CR17","first-page":"18476","volume":"8","author":"JM Yuan","year":"2015","unstructured":"Yuan JM, Shi XJ, Sun P, Liu JX, Wang W, Li M, et al. Downregulation of cell cycle-related proteins in ovarian cancer line and cell cycle arrest induced by microRNA. Int J Clin Exp Med. 2015;8(10):18476\u201381.","journal-title":"Int J Clin Exp Med"},{"issue":"7","key":"202_CR18","doi-asserted-by":"publisher","first-page":"e0199688","DOI":"10.1371\/journal.pone.0199688","volume":"13","author":"J Xu","year":"2018","unstructured":"Xu J, Lin DI. Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas. PLoS One. 2018;13(7):e0199688. https:\/\/doi.org\/10.1371\/journal.pone.0199688.","journal-title":"PLoS One"},{"issue":"11","key":"202_CR19","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/aje\/kwr002","volume":"173","author":"H Cai","year":"2011","unstructured":"Cai H, Xiang YB, Qu S, Long J, Cai Q, Gao J, et al. Association of genetic polymorphisms in cell-cycle control genes and susceptibility to endometrial cancer among Chinese women. Am J Epidemiol. 2011;173(11):1263\u201371. https:\/\/doi.org\/10.1093\/aje\/kwr002.","journal-title":"Am J Epidemiol"},{"key":"202_CR20","doi-asserted-by":"publisher","unstructured":"Lin Y, Lin Z, Fang Z, Li H, Zhi X, Zhang Z. Plasma MicroRNA-34a as a potential biomarker for early diagnosis of esophageal cancer. Clin Lab. 2019;65(11). doi:https:\/\/doi.org\/10.7754\/Clin.Lab.2019.190340.","DOI":"10.7754\/Clin.Lab.2019.190340"},{"key":"202_CR21","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1002\/jcp.29363","volume":"235","author":"X Ge","year":"2019","unstructured":"Ge X, Gao J, Sun QW, Wang CX, Deng W, Mao GY, et al. MiR-34a inhibits the proliferation, migration, and invasion of oral squamous cell carcinoma by directly targeting SATB2. J Cell Physiol. 2019;235:4856\u201364. https:\/\/doi.org\/10.1002\/jcp.29363.","journal-title":"J Cell Physiol"},{"issue":"13","key":"202_CR22","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1167\/iovs.18-26477","volume":"60","author":"Q Hou","year":"2019","unstructured":"Hou Q, Han S, Yang L, Chen S, Chen J, Ma N, et al. The interplay of MicroRNA-34a, LGR4, EMT-associated factors, and MMP2 in regulating uveal melanoma cells. Invest Ophthalmol Vis Sci. 2019;60(13):4503\u201310. https:\/\/doi.org\/10.1167\/iovs.18-26477.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"202_CR23","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027\u201334. https:\/\/doi.org\/10.1084\/jem.192.7.1027.","journal-title":"J Exp Med"},{"issue":"26","key":"202_CR24","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455\u201365. https:\/\/doi.org\/10.1056\/NEJMoa1200694.","journal-title":"N Engl J Med"},{"issue":"21","key":"202_CR25","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1501824.","journal-title":"N Engl J Med"},{"key":"202_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/PAS.0000000000001395","volume":"44","author":"A Pasanen","year":"2019","unstructured":"Pasanen A, Ahvenainen T, Pellinen T, Vahteristo P, Loukovaara M, Butzow R. PD-L1 expression in endometrial carcinoma cells and intratumoral immune cells: differences across histologic and TCGA-based molecular subgroups. Am J Surg Pathol. 2019;44:174\u201381. https:\/\/doi.org\/10.1097\/PAS.0000000000001395.","journal-title":"Am J Surg Pathol"},{"issue":"21","key":"202_CR27","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1158\/0008-5472.CAN-19-1302","volume":"79","author":"T Fukumoto","year":"2019","unstructured":"Fukumoto T, Fatkhutdinov N, Zundell JA, Tcyganov EN, Nacarelli T, Karakashev S, et al. HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer. Cancer Res. 2019;79(21):5482\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-1302.","journal-title":"Cancer Res"},{"key":"202_CR28","doi-asserted-by":"publisher","unstructured":"Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543(7645):378\u201384. doi:https:\/\/doi.org\/10.1038\/nature21386.","DOI":"10.1038\/nature21386"},{"issue":"4","key":"202_CR29","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1172\/JCI120803","volume":"128","author":"H Lin","year":"2018","unstructured":"Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest. 2018;128(4):1708. https:\/\/doi.org\/10.1172\/JCI120803.","journal-title":"J Clin Invest"},{"issue":"6","key":"202_CR30","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s00432-019-02915-1","volume":"145","author":"F Thangarajah","year":"2019","unstructured":"Thangarajah F, Morgenstern B, Pahmeyer C, Schiffmann LM, Puppe J, Mallmann P, et al. Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva. J Cancer Res Clin Oncol. 2019;145(6):1651\u201360. https:\/\/doi.org\/10.1007\/s00432-019-02915-1.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"202_CR31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s13287-017-0706-z","volume":"8","author":"Z Liang","year":"2017","unstructured":"Liang Z, Chen Y, Zhao Y, Xu C, Zhang A, Zhang Q, et al. miR-200c suppresses endometriosis by targeting MALAT1 in vitro and in vivo. Stem Cell Res Ther. 2017;8(1):251. https:\/\/doi.org\/10.1186\/s13287-017-0706-z.","journal-title":"Stem Cell Res Ther"},{"key":"202_CR32","doi-asserted-by":"publisher","unstructured":"Peng Y, Fan JY, Xiong J, Lou Y, Zhu Y. miR-34a enhances the susceptibility of gastric cancer to platycodin D by targeting survivin. Pathobiology. 2019:1\u201310. doi:https:\/\/doi.org\/10.1159\/000502913.","DOI":"10.1159\/000502913"},{"key":"202_CR33","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1038\/ncomms3977","volume":"5","author":"A Parikh","year":"2014","unstructured":"Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V, et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun. 2014;5:2977. https:\/\/doi.org\/10.1038\/ncomms3977.","journal-title":"Nat Commun"},{"issue":"2","key":"202_CR34","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.3892\/mmr.2016.5413","volume":"14","author":"M Zhu","year":"2016","unstructured":"Zhu M, Zhou X, Du Y, Huang Z, Zhu J, Xu J, et al. miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD. Mol Med Rep. 2016;14(2):1742\u201350. https:\/\/doi.org\/10.3892\/mmr.2016.5413.","journal-title":"Mol Med Rep"},{"key":"202_CR35","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jconrel.2016.04.018","volume":"240","author":"S Wang","year":"2016","unstructured":"Wang S, Xu Y, Chan HF, Kim HW, Wang Y, Leong KW, et al. Nanoparticle-mediated inhibition of survivin to overcome drug resistance in cancer therapy. J Control Release. 2016;240:454\u201364. https:\/\/doi.org\/10.1016\/j.jconrel.2016.04.018.","journal-title":"J Control Release"},{"issue":"4","key":"202_CR36","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.3892\/ol.2018.9277","volume":"16","author":"C Zhou","year":"2018","unstructured":"Zhou C, Zhu Y, Lu B, Zhao W, Zhao X. Survivin expression modulates the sensitivity of A549 lung cancer cells resistance to vincristine. Oncol Lett. 2018;16(4):5466\u201372. https:\/\/doi.org\/10.3892\/ol.2018.9277.","journal-title":"Oncol Lett"},{"key":"202_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.gene.2017.10.046","volume":"644","author":"Y Zhou","year":"2018","unstructured":"Zhou Y, Ding BZ, Lin YP, Wang HB. MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1. Gene. 2018;644:56\u201365. https:\/\/doi.org\/10.1016\/j.gene.2017.10.046.","journal-title":"Gene."}],"container-title":["Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-020-00202-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43032-020-00202-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43032-020-00202-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T23:24:14Z","timestamp":1627946654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43032-020-00202-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["202"],"URL":"https:\/\/doi.org\/10.1007\/s43032-020-00202-w","relation":{},"ISSN":["1933-7191","1933-7205"],"issn-type":[{"value":"1933-7191","type":"print"},{"value":"1933-7205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]},"assertion":[{"value":"2 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}